NBI-1065845
NBI-1065845-MDD3024
Phase 3 small_molecule active
Quick answer
NBI-1065845 for Major Depressive Disorder is a Phase 3 program (small_molecule) at NEUROCRINE BIOSCIENCES INC with 5 ClinicalTrials.gov record(s).
Program details
- Company
- NEUROCRINE BIOSCIENCES INC
- Indication
- Major Depressive Disorder
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- active